A phase Ib clinical trial was also conducted in combination with another immune checkpoint inhibitor (the anti-PD-1 antibody Pembrolizumab), targeting untreated patients with stage IIIB to IV melanoma [28]. Here, PDCD1 is linked to melanoma.